BMRN vs. ELAN: BioMarin Pharmaceutical vs. Elanco Animal Health Stock Comparison
How do BioMarin Pharmaceutical (BMRN) and Elanco Animal Health (ELAN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
BioMarin Pharmaceutical (BMRN) and Elanco Animal Health (ELAN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BMRN is classified in Biotechnology while ELAN is classified in Pharmaceuticals.
| Profile Item | BMRN | ELAN |
|---|---|---|
| Name | BioMarin Pharmaceutical Inc. | Elanco Animal Health Incorporated |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Pharmaceuticals |
| GICS Sub-Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 10.85 billion USD | 12.86 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | July 26, 1999 | September 20, 2018 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BMRN | ELAN |
|---|---|---|
| Total Return (1Y) | 8.82% | 24.03% |
| Total Return (3Y, Annualized) | -12.54% | 37.47% |
| Total Return (5Y, Annualized) | -7.51% | -4.24% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Elanco Animal Health (ELAN) has an aggressive beta of 1.65, indicating higher sensitivity to broad-market moves, while BioMarin Pharmaceutical (BMRN) is defensive at 0.24 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.
| Metric | BMRN | ELAN |
|---|---|---|
| Volatility (1Y, Annualized) | 35.50% | 43.57% |
| Beta (5Y) | 0.24 | 1.65 |
| Max Drawdown (5Y) | -57.64% | -75.59% |
| Avg. Volume (3M) | 2.28M | 5.65M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BMRN | ELAN |
|---|---|---|
| Sharpe Ratio (1Y) | 0.13 | 0.45 |
| Sortino Ratio (1Y) | 0.23 | 0.66 |
Profitability
ROE (TTM)
Elanco Animal Health (ELAN) has no ROE value reported for this period; BioMarin Pharmaceutical (BMRN) reports a negative figure of -0.31%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.31%
- Max
- 109.18%
- Q3
- 6.23%
- BMRN
- -0.31%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- ELAN
- --
Net Margin (TTM)
Both BioMarin Pharmaceutical (BMRN) at -0.52% and Elanco Animal Health (ELAN) at -2.86% report negative net margin values, usually indicating net losses over the period.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.52%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- BMRN
- -0.52%
- Q1
- -4.14%
- Min
- -17.05%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-2.86%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- ELAN
- -2.86%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
BioMarin Pharmaceutical (BMRN) at 26.58% operates in the top operating margin quartile, ahead of Elanco Animal Health (ELAN) at 6.64%, which runs around its industry’s norm.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.58%
- Max
- 83.12%
- BMRN
- 26.58%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.64%
- Max
- 83.12%
- Q3
- 14.77%
- ELAN
- 6.64%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BMRN | ELAN |
|---|---|---|
| ROE (TTM) | -0.31% | -- |
| ROA (TTM) | 3.89% | -- |
| Net Margin (TTM) | -0.52% | -2.86% |
| Operating Margin (TTM) | 26.58% | 6.64% |
| Gross Margin (TTM) | 53.21% | 56.18% |
Growth
Revenue Growth
Both BioMarin Pharmaceutical (BMRN) at 12.87% and Elanco Animal Health (ELAN) at 6.22% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
BioMarin Pharmaceutical (BMRN) at -18.55% is around its peer norm for EPS growth, while Elanco Animal Health (ELAN) at -169.12% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | BMRN | ELAN |
|---|---|---|
| Revenue Growth (YoY) | 12.87% | 6.22% |
| Revenue Growth (3Y CAGR) | 15.40% | 2.25% |
| EPS Growth (YoY) | -18.55% | -169.12% |
| EPS Growth (3Y CAGR) | 33.89% | -- |
Financial Strength
Current Ratio (MRQ)
Short-term liquidity can only be read on one side of this pairing: BioMarin Pharmaceutical (BMRN) shows current ratio of 2.44 against its industry benchmark, while Elanco Animal Health (ELAN) has no reading this period.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.44
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BMRN
- 2.44
- Min
- 0.10
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
- ELAN
- --
Debt / Equity (MRQ)
Elanco Animal Health (ELAN) at 0.64 carries an industry-typical debt-to-equity mix, while BioMarin Pharmaceutical (BMRN) at 0.67 uses more debt funding than most peers.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.67
- Max
- 1.42
- BMRN
- 0.67
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.64
- Max
- 1.42
- Q3
- 0.65
- ELAN
- 0.64
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BMRN | ELAN |
|---|---|---|
| Current Ratio (MRQ) | 2.44 | -- |
| Debt / Equity (MRQ) | 0.67 | 0.64 |
| Net Debt / EBITDA | 4.04 | 3.49 |
Dividends
Dividend Yield (TTM)
Neither BioMarin Pharmaceutical (BMRN) nor Elanco Animal Health (ELAN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ELAN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither BioMarin Pharmaceutical (BMRN) nor Elanco Animal Health (ELAN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ELAN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BMRN | ELAN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Neither BioMarin Pharmaceutical (BMRN) nor Elanco Animal Health (ELAN) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BMRN
- --
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- ELAN
- --
P/S Ratio (TTM)
Both BioMarin Pharmaceutical (BMRN) at 2.97 and Elanco Animal Health (ELAN) at 2.50 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.97
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- BMRN
- 2.97
- Min
- 0.01
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.50
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- ELAN
- 2.50
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both BioMarin Pharmaceutical (BMRN) at 1.73 and Elanco Animal Health (ELAN) at 1.95 are valued close to their industries’ norm against book — neither stands out from peers.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.73
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- BMRN
- 1.73
- Q1
- 1.69
- Min
- -5.59
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.95
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- ELAN
- 1.95
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | BMRN | ELAN |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | 2.97 | 2.50 |
| P/B Ratio (MRQ) | 1.73 | 1.95 |
| Free Cash Flow Yield (TTM) | -0.15% | -- |